UniProt P07550
Beta-2 adrenergic receptor (P07550)
Beta-2 adrenergic receptor (UniProt P07550), EC 3.2.1.17: 113 experimental structures and 1 predicted model on GenesisL1, 32 ligands bound, 264 pockets. Binding sites, druggability and experiment against prediction (TM-score) in…
- UniProt
- P07550
- Protein
- Beta-2 adrenergic receptor
- EC
- 3.2.1.17
- Experimental structures
- 113
- Predicted models
- 1
- Ligands
- 32
- Pockets
- 264 · 52 records with a druggable one
Structures
114 records of P07550 in the MolNFT archive: 113 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1GQ4 | Structural determinants of the nherf interaction with BETA2AR and pdgfr | x-ray diffraction | A | — | — |
| 1GQ4 | Structural determinants of the nherf interaction with BETA2AR and pdgfr | x-ray diffraction | A | — | — |
| 2R4R | Crystal structure of the human beta2 adrenoceptor | x-ray diffraction | A | — | — |
| 2R4R | Crystal structure of the human BETA2 adrenoceptor | x-ray diffraction | A | — | — |
| 2R4S | Crystal structure of the human beta2 adrenoceptor | x-ray diffraction | A | — | — |
| 2R4S | Crystal structure of the human BETA2 adrenoceptor | x-ray diffraction | A | — | — |
| 2RH1 | High resolution crystal structure of human B2-adrenergic G protein-coupled receptor. | x-ray diffraction | A | — | — |
| 2RH1 | High resolution crystal structure of human B2-adrenergic G protein- coupled receptor. | x-ray diffraction | A | — | — |
| 3D4S | Cholesterol bound form of human beta2 adrenergic receptor. | x-ray diffraction | A | — | — |
| 3D4S | Cholesterol bound form of human BETA2 adrenergic receptor. | x-ray diffraction | A | — | — |
| 3KJ6 | Crystal structure of a Methylated beta2 Adrenergic Receptor-Fab complex | x-ray diffraction | A | — | — |
| 3KJ6 | Crystal structure of a methylated BETA2 adrenergic receptor-Fab complex | x-ray diffraction | A | — | — |
| 3NY8 | Crystal structure of the human beta2 adrenergic receptor in complex with the inverse agonist ICI… | x-ray diffraction | A | — | — |
| 3NY8 | Crystal structure of the human BETA2 adrenergic receptor in complex with the inverse agonist ici… | x-ray diffraction | A | — | — |
| 3NY9 | Crystal structure of the human beta2 adrenergic receptor in complex with a novel inverse agonist | x-ray diffraction | A | — | — |
| 3NY9 | Crystal structure of the human BETA2 adrenergic receptor in complex with a novel inverse agonist | x-ray diffraction | A | — | — |
| 3NYA | Crystal structure of the human beta2 adrenergic receptor in complex with the neutral antagonist… | x-ray diffraction | A | — | — |
| 3NYA | Crystal structure of the human BETA2 adrenergic receptor in complex with the neutral antagonist… | x-ray diffraction | A | — | — |
| 3P0G | Structure of a nanobody-stabilized active state of the beta2 adrenoceptor | x-ray diffraction | A | — | — |
| 3P0G | Structure of a nanobody-stabilized active state of the BETA2 adrenoceptor | x-ray diffraction | A | — | — |
| 3PDS | Irreversible Agonist-Beta2 Adrenoceptor Complex | x-ray diffraction | A | — | — |
| 3PDS | Irreversible agonist-BETA2 adrenoceptor complex | x-ray diffraction | A | — | — |
| 3SN6 | Crystal structure of the beta2 adrenergic receptor-Gs protein complex | x-ray diffraction | R | — | — |
| 3SN6 | Crystal structure of the BETA2 adrenergic receptor-gs protein complex | x-ray diffraction | R | — | — |
| 4GBR | N-Terminal T4 Lysozyme Fusion Facilitates Crystallization of a G Protein Coupled Receptor | x-ray diffraction | A | — | — |
| 4GBR | N-terminal T4 lysozyme fusion facilitates crystallization of a G protein coupled receptor | x-ray diffraction | A | — | — |
| 4LDE | Structure of beta2 adrenoceptor bound to BI167107 and an engineered nanobody | x-ray diffraction | A | — | — |
| 4LDE | Structure of BETA2 adrenoceptor bound to BI167107 and an engineered nanobody | x-ray diffraction | A | — | — |
| 4LDL | Structure of beta2 adrenoceptor bound to hydroxybenzylisoproterenol and an engineered nanobody | x-ray diffraction | A | — | — |
| 4LDL | Structure of BETA2 adrenoceptor bound to hydroxybenzylisoproterenol and an engineered nanobody | x-ray diffraction | A | — | — |
| 4LDO | Structure of beta2 adrenoceptor bound to adrenaline and an engineered nanobody | x-ray diffraction | A | — | — |
| 4LDO | Structure of BETA2 adrenoceptor bound to adrenaline and an engineered nanobody | x-ray diffraction | A | — | — |
| 4QKX | Structure of beta2 adrenoceptor bound to a covalent agonist and an engineered nanobody | x-ray diffraction | A | — | — |
| 4QKX | Structure of BETA2 adrenoceptor bound to a covalent agonist and an engineered nanobody | x-ray diffraction | A | — | — |
| 5D5A | In meso in situ serial X-ray crystallography structure of the Beta2-adrenergic receptor at 100 K | x-ray diffraction | A | BGC, GLC, CAU, ACM, CLR, PLM | — |
| 5D5A | In meso in situ serial X-ray crystallography structure of the BETA2- adrenergic receptor at 100 K | x-ray diffraction | A | — | — |
| 5D5B | In meso X-ray crystallography structure of the BETA2-adrenergic receptor at 100 K | x-ray diffraction | A | — | — |
| 5D6L | beta2AR-T4L - CIM | x-ray diffraction | A | BGC, GLC, SO4, CAU, ACM, CLR | 3 (best 0.80) |
| 5D6L | BETA2AR-T4L - cim | x-ray diffraction | A | — | — |
| 5JQH | Structure of beta2 adrenoceptor bound to carazolol and inactive-state stabilizing nanobody, Nb60 | x-ray diffraction | A, B | CAU, CLR | — |
| 5JQH | Structure of BETA2 adrenoceptor bound to carazolol and inactive-state stabilizing nanobody, NB60 | x-ray diffraction | A, B | — | — |
| 5X7D | Structure of BETA2 adrenoceptor bound to carazolol and an intracellular allosteric antagonist | x-ray diffraction | A | CLR, CAU, ACM | — |
| 6E67 | Structure of BETA2 adrenergic receptor fused to a gs peptide | x-ray diffraction | A, B | P0G | — |
| 6MXT | Crystal structure of human beta2 adrenergic receptor bound to salmeterol and Nb71 | x-ray diffraction | A | K5Y, MG, NI, HTO, OLA | 6 (best 0.78) |
| 6MXT | Crystal structure of human BETA2 adrenergic receptor bound to salmeterol and NB71 | x-ray diffraction | A | K5Y, MG, NI, HTO, OLA | — |
| 6N48 | Structure of beta2 adrenergic receptor bound to BI167107, Nanobody 6B9, and a positive allosteric… | x-ray diffraction | A | P0G, 1WV, KBY | — |
| 6N48 | Structure of BETA2 adrenergic receptor bound to BI167107, nanobody 6B9, and a positive allosteric… | x-ray diffraction | A | P0G, 1WV, KBY | — |
| 6NI3 | B2V2R-Gs protein subcomplex of a GPCR-G protein-beta-arrestin mega-complex | electron microscopy | R | P0G | — |
| 6NI3 | B2V2R-gs protein subcomplex of a GPCR-G protein-beta-arrestin mega- complex | electron microscopy | R | P0G | — |
| 6OBA | The beta2 adrenergic receptor bound to a negative allosteric modulator | x-ray diffraction | A | CLR, JTZ, M3J | 4 (best 0.79) |
| 6OBA | The BETA2 adrenergic receptor bound to a negative allosteric modulator | x-ray diffraction | A | CLR, JTZ, M3J | — |
| 6PRZ | Xfel BETA2 ar structure by ligand exchange from alprenolol to alprenolol. | x-ray diffraction | A | JTZ, CLR, OLA, SO4 | — |
| 6PS0 | Xfel BETA2 ar structure by ligand exchange from alprenolol to carazolol. | x-ray diffraction | A | CAU, SO4, CLR, OLA | — |
| 6PS1 | Xfel BETA2 ar structure by ligand exchange from alprenolol to timolol. | x-ray diffraction | A | TIM, SO4, CLR, OLA | — |
| 6PS2 | Xfel BETA2 ar structure by ligand exchange from timolol to alprenolol. | x-ray diffraction | A | JTZ, CLR, OLB, SO4, OLA | — |
| 6PS3 | XFEL beta2 AR structure by ligand exchange from Timolol to Carvedilol. | x-ray diffraction | A | CVD, SO4, CLR, OLA | 6 (best 0.78) |
| 6PS3 | Xfel BETA2 ar structure by ligand exchange from timolol to carvedilol. | x-ray diffraction | A | CVD, SO4, CLR, OLA | — |
| 6PS4 | Xfel BETA2 ar structure by ligand exchange from timolol to ici-118551. | x-ray diffraction | A | JRZ, SO4, CLR, OLA | — |
| 6PS5 | Xfel BETA2 ar structure by ligand exchange from timolol to propranolol. | x-ray diffraction | A | SNP, SO4, CLR, OLA | — |
| 6PS6 | Xfel BETA2 ar structure by ligand exchange from timolol to timolol. | x-ray diffraction | A | TIM, SO4, CLR, OLA | — |
54 records more on the page itself.
Ligands
- G1I · (5R,6R)-6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2,5-triol · in 45 records
- CLR · Cholesterol · in 15 records
- OLA · Oleic acid · in 11 records
- SO4 · Sulfate ion · in 11 records
- CAU · (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol · in 5 records
- JTZ · (2S)-1-[(1-methylethyl)amino]-3-(2-prop-2-en-1-ylphenoxy)propan-2-ol · in 5 records
- P0G · 8-[(1R)-2-{[1,1-dimethyl-2-(2-methylphenyl) ethyl]amino}-1-hydroxyethyl]-5-hydroxy-2H-1,4-benzoxazin-3(4H)-one · in 5 records
- ACM · Acetamide · in 3 records
- 1WV · (2S)-2,3-dihydroxypropyl (7Z)-tetradec-7-enoate · in 2 records
- 5FW · Isoprenaline · in 2 records
- BGC · beta-D-glucopyranose · in 2 records
- CVD · (2S)-1-(8H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy) ethylamino]propan-2-ol · in 2 records
- GLC · alpha-D-glucopyranose · in 2 records
- HTO · Heptane-1,2,3-triol · in 2 records
- K5Y · salmeterol · in 2 records
- KBY · N-[(3R)-4-(4-tert-butylphenyl)-3-({2-[(4-methoxyphenyl)sulfanyl]-5-[methyl(propan-2-yl) sulfamoyl]benzene-1-carbonyl}amino)butanoyl]glycine · in 2 records
- M3J · 6-bromo-N~2~-phenylquinazoline-2,4-diamine · in 2 records
- MG · Magnesium ion · in 2 records
- NA · Sodium ion · in 2 records
- NI · Nickel (II) ion · in 2 records
- PLM · Palmitic acid · in 2 records
- TIM · (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol · in 2 records
- 68H · Salbutamol · in 1 record
- A1AE2 · (2S)-1-[(3-{1-[4-(4-{(2S)-2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)butyl]-1H-1,2,3-triazol-4-yl}propyl)amino]-3-(2-propylphenoxy)propan-2-ol · in 1 record
- AV0 · 2-decyl-2-{[(4-O-alpha-D-glucopyranosyl-beta-D-glucopyranosyl)oxy]methyl}dodecyl 4-O-alpha-D-glucopyranosyl-beta-D-glucopyranoside · in 1 record
- E5E · Noradrenaline · in 1 record
- FK5 · 8-deethyl-8-[but-3-enyl]-ascomycin · in 1 record
- GJ6 · (5R,6R)-6-(propan-2-ylamino)-5,6,7,8-tetrahydronaphthalene-1,2,5-triol · in 1 record
- JRZ · (2S,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]butan-2-ol · in 1 record
- OLB · (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate · in 1 record
Experiment against prediction
- 4GBR chain A against the predicted model P07550: TM-score 0.98, RMSD 1.21 Å
- 4GBR chain A against the predicted model P07550: TM-score 0.98, RMSD 1.21 Å
- 8GE9 chain R against the predicted model P07550: TM-score 0.95, RMSD 1.76 Å
- 8GE8 chain R against the predicted model P07550: TM-score 0.95, RMSD 1.77 Å
- 8GEA chain R against the predicted model P07550: TM-score 0.95, RMSD 1.77 Å
- 8GEF chain R against the predicted model P07550: TM-score 0.95, RMSD 1.80 Å
- 8GED chain R against the predicted model P07550: TM-score 0.94, RMSD 1.82 Å
- 8GEG chain R against the predicted model P07550: TM-score 0.94, RMSD 1.82 Å
- 8GEB chain R against the predicted model P07550: TM-score 0.94, RMSD 1.80 Å
- 8GE5 chain R against the predicted model P07550: TM-score 0.94, RMSD 1.92 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.